152 related articles for article (PubMed ID: 9423940)
21. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.
Pekna M; Borowiec J; Fagerhol MK; Venge P; Thelin S
Scand J Thorac Cardiovasc Surg; 1994; 28(1):5-11. PubMed ID: 7939508
[TBL] [Abstract][Full Text] [Related]
22. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
23. Coating of extracorporeal circuit with heparin does not prevent sequestration of propofol in vitro.
Hammarén E; Rosenberg PH; Hynynen M
Br J Anaesth; 1999 Jan; 82(1):38-40. PubMed ID: 10325833
[TBL] [Abstract][Full Text] [Related]
24. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
Fukutomi M; Kobayashi S; Niwaya K; Hamada Y; Kitamura S
Artif Organs; 1996 Jul; 20(7):767-76. PubMed ID: 8828766
[TBL] [Abstract][Full Text] [Related]
25. The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation.
Korn RL; Fisher CA; Livingston ER; Stenach N; Fishman SJ; Jeevanadam V; Addonizio VP
J Thorac Cardiovasc Surg; 1996 May; 111(5):1073-84. PubMed ID: 8622305
[TBL] [Abstract][Full Text] [Related]
26. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass.
Fosse E; Moen O; Johnson E; Semb G; Brockmeier V; Mollnes TE; Fagerhol MK; Venge P
Ann Thorac Surg; 1994 Aug; 58(2):472-7. PubMed ID: 8067851
[TBL] [Abstract][Full Text] [Related]
27. Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit.
Moen O; Fosse E; Bråten J; Andersson C; Høgåsen K; Mollnes TE; Venge P; Kierulf P
Perfusion; 1996 Mar; 11(2):113-23. PubMed ID: 8740352
[TBL] [Abstract][Full Text] [Related]
28. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model.
Bannan S; Danby A; Cowan D; Ashraf S; Gesinde M; Martin P
Eur J Cardiothorac Surg; 1997 Aug; 12(2):268-75. PubMed ID: 9288518
[TBL] [Abstract][Full Text] [Related]
29. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility.
Moen O; Fosse E; Dregelid E; Brockmeier V; Andersson C; Høgåsen K; Venge P; Mollnes TE; Kierulf P
Ann Thorac Surg; 1996 Oct; 62(4):1134-40. PubMed ID: 8823102
[TBL] [Abstract][Full Text] [Related]
30. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass.
Moen O; Høgåsen K; Fosse E; Dregelid E; Brockmeier V; Venge P; Harboe M; Mollnes TE
Ann Thorac Surg; 1997 Jan; 63(1):105-11. PubMed ID: 8993250
[TBL] [Abstract][Full Text] [Related]
31. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery.
Olsson C; Siegbahn A; Henze A; Nilsson B; Venge P; Joachimsson PO; Thelin S
Scand Cardiovasc J; 2000; 34(1):33-40. PubMed ID: 10816058
[TBL] [Abstract][Full Text] [Related]
32. Human neutrophil degranulation during extracorporeal circulation.
Wachtfogel YT; Kucich U; Greenplate J; Gluszko P; Abrams W; Weinbaum G; Wenger RK; Rucinski B; Niewiarowski S; Edmunds LH
Blood; 1987 Jan; 69(1):324-30. PubMed ID: 2947645
[TBL] [Abstract][Full Text] [Related]
33. The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass.
Muriithi EW; Belcher PR; Rao JN; Chaudhry MA; Nicol D; Wheatley DJ
J Thorac Cardiovasc Surg; 2000 Sep; 120(3):538-43. PubMed ID: 10962416
[TBL] [Abstract][Full Text] [Related]
34. The impact of heparin coated circuits upon metabolism in vital organs: effect upon cerebral and renal function during and after cardiopulmonary bypass.
de Vroege R; Stooker W; van Oeveren W; Bakker EW; Huybregts RA; van Klarenbosch J; van Kamp GJ; Hack CE; Eijsman L; Wildevuur CR
ASAIO J; 2005; 51(1):103-9. PubMed ID: 15745143
[TBL] [Abstract][Full Text] [Related]
35. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits.
Gunaydin S; Mccusker K; Vijay V
J Extra Corpor Technol; 2005 Sep; 37(3):290-5. PubMed ID: 16350383
[TBL] [Abstract][Full Text] [Related]
36. Serum and plasma measurements of neutrophil granule proteins during cardiopulmonary bypass: a model to estimate human turnover of lactoferrin and myeloperoxidase.
Venge P; Nilsson L; Nyström SO; Aberg T
Eur J Haematol; 1987 Oct; 39(4):339-45. PubMed ID: 2826224
[TBL] [Abstract][Full Text] [Related]
37. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
[TBL] [Abstract][Full Text] [Related]
38. Nitric oxide and inflammatory response in simulated extracorporeal circulation.
Lahtinen M; Melki V; Adamik B; Khamis H; Borowiec JW
Thorac Cardiovasc Surg; 2003 Jun; 51(3):130-7. PubMed ID: 12833201
[TBL] [Abstract][Full Text] [Related]
39. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass.
Gu YJ; van Oeveren W; Akkerman C; Boonstra PW; Huyzen RJ; Wildevuur CR
Ann Thorac Surg; 1993 Apr; 55(4):917-22. PubMed ID: 8466349
[TBL] [Abstract][Full Text] [Related]
40. Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients.
Hamulu A; Dişcigil B; Ozbaran M; Calkavur T; Kara E; Kokuludağ A; Büket S; Bilkay O
Perfusion; 1996 Jul; 11(4):333-7. PubMed ID: 8884862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
